Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Neoadjuvant Chemoradiotherapy Plus Tislelizumab Followed by TME for LARC.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04911517
Recruitment Status : Not yet recruiting
First Posted : June 3, 2021
Last Update Posted : October 20, 2021
Sponsor:
Collaborators:
Hangzhou New Horizon Health Technology Co., Ltd.
Beigene (Beijing) Biotechnology Co., Ltd
Beijing Chao Yang Hospital
Xuanwu Hospital, Beijing
Tianjin Medical University General Hospital
People's Hospital of Tianjin
Tianjin Medical University Cancer Institute & Hospital
China-Japan Friendship Hospital
Information provided by (Responsible Party):
Zhongtao Zhang, Beijing Friendship Hospital

Brief Summary:

Long course radiotherapy plus neoadjuvant chemotherapy followed by resection total mesorecta excision has accepted widespread recognized in the treatment of locally advanced rectal cancer (LARC). Tislelizumab, an anti-PD1(programmed death 1) humanized IgG4 (Immunoglomin G4) monoclonal antibody, has been demonstrated with clinical activity and is approved for treating recurrent/refractory classical Hodgkin lymphoma and locally advanced/metastatic urothelial carcinoma in China.

The aim of This NCRT-PD-1-LARC trial is to evaluate the efficacy and safety of long course neoadjuvant chemoradiotherapy plus tislelizumab followed by total mesorecta excision for LARC. This NCRT-PD-1-LARC trial will be a prospective, multicenter and phase Ⅱ clinical trial designed to evaluate the safety and efficacy of LARC patients treated with long course neoadjuvant chemoradiotherapy plus tislelizumab followed by total mesorecta excision. It will consecutively enroll 50 stage II/III LARC patients (cT3N0M0 and cT1-3N1-2M0) with the tumor distal location ≤ 10cm from anal verge at 7 centers in China. The enrolled patients will receive long course radiotherapy (50 Gy/25 f, 2 Gy/f, 5 days/week) and three 21-day cycles capecitabine (1000 mg/m2, bid, po, day1-14) plus three 21-day cycles tislelizumab (200 mg, iv.gtt, day8), followed by total mesorecta excision 6-8 week after the end of radiotherapy. The primary efficacy endpoint will be the pathological complete response (pCR) rate, which is defined as absence of viable tumor cells in the primary tumor and lymph nodes.


Condition or disease Intervention/treatment Phase
Colorectal Neoplasms Combination Product: long course radiotherapy + capecitabine + PD-1 monoclonal antibody treatment combinations Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: The enrolled patients in this NCRT-PD-1-LARC trial will receive long course radiotherapy (50 Gy/25 f, 2 Gy/f, 5 days/week) and three 21-day cycles capecitabine (1000 mg/m2, bid, po, day1-14) plus three 21-day cycles tislelizumab (200 mg, iv.gtt, day8), followed by total mesorecta excision 6-8 week after the end of radiotherapy.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Rationale and Design of a Prospective, Multicenter Phase Ⅱ Clinical Trial of Safety and Efficacy Evaluation of Long Course Neoadjuvant Chemoradiotherapy Plus Tislelizumab Followed by TME for LARC.
Estimated Study Start Date : October 2021
Estimated Primary Completion Date : May 2022
Estimated Study Completion Date : May 2024

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: long course radiotherapy + capecitabine + PD-1 monoclonal antibody treatment combinations
long course radiotherapy + capecitabine + PD-1 monoclonal antibody treatment combinations in patients with locally advanced rectal cancer
Combination Product: long course radiotherapy + capecitabine + PD-1 monoclonal antibody treatment combinations
long course radiotherapy + capecitabine + PD-1 monoclonal antibody treatment combinations in patients with locally advanced rectal cancer




Primary Outcome Measures :
  1. pathologic complete response(pCR) [ Time Frame: 1 year ]
    All the enrolled patients will receive total mesorectal excision (TME) 7-9 weeks after the end of long course radiotherapy. The rectal specimens will be evaluated by the pathologists who are experienced on the rectal cancer diagnosis according to the 1997 Dworak grading system. The rectal cancer will be classified into 5 grades. Grade 0-3 will be considered as non-pCR while grade 4 represent pCR.


Secondary Outcome Measures :
  1. neoadjuvant rectal (NAR) score [ Time Frame: 1 year ]
    The neoadjuvant rectal (NAR) score is a promising indicator of survival after preoperative chemoradiotherapy for rectal cancer. The NAR score was calculated according to the following formula: NAR score = [5pN - 3(cT - pT) + 12]2∕9.61. (clinical tumor (cT) stage, pathologic tumor (pT) stage, pathologic nodal (pN) stage)

  2. objective response rate (ORR) [ Time Frame: 1 year ]
    ORR is evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. The ORR rate is the sum of complete response (CR) and partial response (PR)

  3. R0 resection rate [ Time Frame: 1 year ]
    During the surgical process, the surgeon will evaluate the level of cancer resection. It will be classified as R0, R1, R2 resection. Therefore, we can calculate R0 resection rate.

  4. anal preservation rate [ Time Frame: 1 year ]
    the surgeon will decide whether the anal can be preserved on the basis of the rectal cancer and intraoperative situation. anal preservation rate is the percentage of patients who achieve anal preservation.

  5. 3-year local recurrence rate (LRR) [ Time Frame: 3 year ]
    During the 3-year follow-up, the percentage of local recurrence.

  6. 3-year disease free survival (DFS) [ Time Frame: 3 year ]
    During the 3-year follow-up, the percentage of the patients who is disease free.

  7. 3-year overall survival (OS) [ Time Frame: 3 year ]
    During the 3-year follow-up, the percentage of the patients who is sill survival at the end of follow-up.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  • Patients have been fully aware of the content of this study and signed the informed consent voluntarily;
  • Patients with rectal cancers must satisfied all the following conditions: Stage II/III LARC (cT1-3N1-2M0);Tumor distal location ≤10 cm from anal verge (MRI diagnosed);
  • Patients regardless of gender with aged ≥18 years and ECOG score of 0 or 1;
  • Physical and viscera function of patients can withstand major abdominal surgery;
  • Patients are willing and able to follow the study protocol during the study;
  • Patients give consent to the use of blood and pathological specimens for study;
  • Within 28 days prior to enrolment, we must confirm a negative serological pregnancy test for child-bearing age women and they agree to use effective contraception for the duration of drug use and for 60 days after the last dose.

Exclusion criteria:

  • Patients have a present or previous active malignancy except the diagnosis of rectal cancer this time;
  • Patients underwent major surgery within 4 weeks prior to study treatment;
  • Patients have any condition affects the absorption of capecitabine through gastrointestinal tract;
  • Patients have severe uncontrolled recurrent infections, or other severe uncontrolled concomitant diseases;
  • Patients who are allergic to any of the ingredients under study;
  • Patients with severe concomitant diseases with estimated survival ≤ 5 years;
  • Patients with present or previous moderate or severe liver and kidney damage presently or previously;
  • Patients have received other study medications or any immunotherapy currently or in the past;
  • Patients preparing for or previously received organ or bone marrow transplant;
  • Patients who received immunosuppressive or systemic hormone therapy for immunosuppressive purposes within 1 month prior to the initiation of study therapy;
  • Patients with congenital or acquired immune deficiency (such as HIV infection);
  • If patients with a history of uncontrolled epilepsy, central nervous system disease or mental disorder, the investigator will determine whether the clinical severity prevents the signing of informed consent or affects the patient's oral medication compliance;
  • Patients with other factors that may affect the study results or cause the study to be terminated midway, such as alcoholism, drug abuse, other serious diseases (including mental illness) requiring combined treatment and severe laboratory examination abnormalities.
  • Pregnant or lactating women

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04911517


Contacts
Layout table for location contacts
Contact: Hongwei Yao, Dr. +8613611015609 ext 63139203 yaohongwei@ccmu.edu.cn

Locations
Layout table for location information
China, Beijing
Beijing Friendship Hospital
Beijing, Beijing, China, 100050
Sponsors and Collaborators
Beijing Friendship Hospital
Hangzhou New Horizon Health Technology Co., Ltd.
Beigene (Beijing) Biotechnology Co., Ltd
Beijing Chao Yang Hospital
Xuanwu Hospital, Beijing
Tianjin Medical University General Hospital
People's Hospital of Tianjin
Tianjin Medical University Cancer Institute & Hospital
China-Japan Friendship Hospital
Investigators
Layout table for investigator information
Study Chair: yaohongwei@ccmu.edu.cn Yao, Dr. Department of General Surgery, Beijing Friendship Hospital, Capital Medical University
Publications:

Layout table for additonal information
Responsible Party: Zhongtao Zhang, professor, Beijing Friendship Hospital
ClinicalTrials.gov Identifier: NCT04911517    
Other Study ID Numbers: BFH-NCRTPD
First Posted: June 3, 2021    Key Record Dates
Last Update Posted: October 20, 2021
Last Verified: October 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
Clinical Study Report (CSR)
Analytic Code
Time Frame: 2025.5-
Access Criteria: via reasonable email requests

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Zhongtao Zhang, Beijing Friendship Hospital:
Colorectal Neoplasms
Programmed Cell Death 1 Receptor
Neoadjuvant Therapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Colorectal Neoplasms
Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Capecitabine
Antibodies
Antibodies, Monoclonal
Immunologic Factors
Physiological Effects of Drugs
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents